Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use CINQAIR safely and effectively. See full prescribing information for CINQAIR.CINQAIR® (reslizumab) injection, for intravenous useInitial U.S. Approval: 2016
Medication labelWhy this: Advisory · dailymed-prescription
CINQAIR® is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype [see Clinical Studies (14)]. Limitation of Use: CINQAIR is not indicated for treatment of other eosinophilic conditions. CINQAIR is not indicated for the relief of acute bronchospasm or status asthmaticus [see Warnings and Precautions (5.2)].
- generic_name
- reslizumab
- product_names
- Reslizumab
- ndc
- 59310-610, 59310-610-31, 59310-610-33
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en